Aktienanalyse zu Ionis Pharmaceuticals Inc (IONS)IONSIonis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Ionis Pharmaceuticals is currently a hold. The stock price is at $45.28, and while it has shown a recent 5-day increase of 4.00%, it is down 43.17% year-to-date. The forward P/E ratio is high at 90.91, indicating potential overvaluation, while the gross margin remains strong at 98.98%. However, the recent revenue decline of 41% compared to Alnylam's growth highlights competitive challenges. The main risk is the high forward P/E ratio, suggesting that the stock may not be a good buy at this price.

15 analysts cover IONS: 5 rate it Buy, 8 Hold and 2 Sell. The average price target is 92.67.